Loading
Virtual Incision
  • Virtual Incision
    • About
    • Company Values
    • Leadership Team
    • Recent News
      • Newsroom
  • miniRAS
  • MIRA
    • Components
    • Space Age Technology
  • Safety Information
  • Careers
  • Contact
  • Menu Menu

Virtual Incision Expands Leadership Team as it Prepares for New Market Growth

Press Release

International industry executive Piet Hinoul joins Virtual Incision as chief medical officer, Dmitry Oleynikov transitions to chief surgeon

Lincoln, Neb. – March 28, 2023 – Virtual Incision Corporation, a medical device company developing the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced the appointment of global healthcare executive Piet Hinoul, MD, PhD, as chief medical officer (CMO). The company’s current CMO Dmitry Oleynikov, MD, FACS will take on the newly established role of chief surgeon, focusing on the research and development of new RAS technology. The expansion of the team strengthens Virtual Incision at a transformative point in its trajectory as it develops new market growth strategies for its MIRA Surgical System.

In addition to Dr. Oleynikov’s current role as the chair of the Department of Surgery at Monmouth Medical Center, he will continue to support Virtual Incision’s efforts in the area of robotic-assisted minimally invasive general surgery under his new role as chief surgeon. He has contributed to over 200 peer-reviewed articles, 250 abstract presentations, 11 issued patents, and 42 patent applications in the area of surgical robotics and surgical outcomes research. He was a critical stakeholder in the development of the MIRA Surgical System alongside Shane Farritor, MS, PhD, co-founder and chief technology officer of Virtual Incision.

“During Dr. Oleynikov’s tenure as CMO, we have evolved into a mature company with a miniaturized system that has the potential to impact millions of patients,” said John Murphy, president and chief executive officer of Virtual Incision. “We’re thankful for his continued contributions to Virtual Incision and his dedication to helping make MIRA a reality.”

Dr. Hinoul brings 30 years of healthcare experience to Virtual Incision, of which the past 15 have been spent in the MedTech industry. Most recently, Dr. Hinoul served as senior vice president and global head of medical affairs for the oncology company Novocure (NASDAQ: NVCR). Prior to that, he was the global head of preclinical, clinical, and medical affairs for Ethicon, Inc., the surgical subsidiary of Johnson & Johnson (NYSE: JNJ). Beyond his industry expertise, Dr. Hinoul is a European board-certified gynecologist with 15 years of clinical practice. He is widely published and has lectured internationally in the fields of urogynecology, surgery, and medical device innovation.

"Clinical excellence has served as the bedrock of Virtual Incision since its inception in 2006, and our commitment to that excellence is reinforced by the addition of Dr. Hinoul to our leadership team,” said John Murphy. “He is an accomplished global physician executive with a demonstrated track record of success. I am confident Dr. Hinoul’s broad experience with post-market medical affairs activities, in addition to his clinical background in women’s health, will critically boost our ability for future planning and execution in the U.S. and internationally on a variety of indications for MIRA. ”

About the MIRA Surgical System 

MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek design is planned to offer the benefits of RAS during bowel resection procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company is developing MIRA, the first-of-its-kind miniature RAS platform. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and Twitter.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

https://virtualincision.com/wp-content/uploads/2023/03/oie_28133557N51NBYDL.jpg 354 600 jeremiah /wp-content/uploads/2022/08/logo-mrk-wht.svg jeremiah2023-03-28 04:59:422023-03-29 08:51:03Virtual Incision Expands Leadership Team as it Prepares for New Market Growth
March 18, 2025

Virtual Incision Explores NVIDIA Isaac for Healthcare in Surgical Robotics

November 25, 2024

U.S.-Based Remote Robotic-Assisted Surgery Demonstration Successfully Completed Through Collaborations with Virtual Incision, Sovato, City of Hope, and University of Illinois Chicago

July 30, 2024

Virtual Incision Announces Successful Completion of the First Hysterectomy Performed with the MIRA™ Surgical System

April 30, 2024

Virtual Incision Announces Publication of Data from its U.S. Investigational Device Exemption Study in the Clinical Journal, Diseases of Colon and Rectum

April 10, 2024

Virtual Incision to Showcase Miniaturized Robotic-Assisted Surgery at SAGES 2024

March 18, 2024

Virtual Incision’s MIRA Surgical System to be Featured Among Elite AI-Enabled Innovations at NVIDIA GTC

February 24, 2024

Virtual Incision Receives FDA Authorization for the MIRA Surgical System as the First Miniaturized Robotic-Assisted Surgery Device

February 13, 2024

Surgery in space: Tiny remotely operated robot completes first simulated procedure at the space station

Disclosure and Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. Patients and doctors should review all available information on nonsurgical and surgical options and associated risks in order to make an informed decision.

Serious complications may occur in any surgery, including minimally invasive surgery with the MIRA Surgical System, up to and including death. Serious risks include, but are not limited to, injury to tissues and organs, and/or conversion to other surgical techniques which could result in a longer operative time and/or complications.

For important safety information, including surgical risks and considerations, please also refer to www.virtualincision.com/safety-information. For the product’s indications for use, risks, full cautions, and warnings, please refer to the associated user manual(s).

Individual outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics, surgeon, and/or hospital experience.

MIRA Surgical System Precaution Statement

The demonstration of safety and effectiveness for the representative specific procedures was based on evaluation of the MIRA Surgical System as a surgical device and did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence) or treatment of the patient’s underlying disease/condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon.

Contact

Virtual Incision
1501 Old Cheney Rd
Lincoln, NE 68512

  • Privacy Policy
  • Terms of Use
  • @virtualincision
  • @MIRA_by_VIC
  • VirtualIncisionCorporation
  • Virtual Incision media contact
  • Opportunities with Virtual Incision

Sign up today to be the first to get Virtual Incision news and updates

SIGN UP
Back to Top
2024 © Copyright - Virtual Incision®
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only